Precipio expands Bloodhound MPN panel by adding CALR mutation subtyping

Precipio announces the launch of a new version of its Bloodhound MPN panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network guidelines released in August of this year. This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN.